Home › Corona Remedies › Revenue History

Corona Remedies Revenue History — Quarter by Quarter

Corona Remedies's revenue moved from ₹361 Cr in Q2 FY26 to ₹353 Cr in Q4 FY26, a -2.2% change over 3 quarters. The table keeps each quarter linked back to the underlying earnings page.

Revenue by Quarter

Quarter	Revenue (₹ Cr)	YoY Change
Q4 FY26	₹353 Cr	+17.3%
Q2 FY26	₹361 Cr	+15%
Q3 FY26	₹342 Cr	+15%

What management said about revenue

Q4 FY26 · 15% organic revenue growth in FY27

Management expects to sustain 15%+ revenue growth organically for FY27.

Q4 FY26 · 25% revenue growth on acquired brands

Acquired brands (Wokadin, Bayer portfolio) are expected to grow at 25% in FY27.

Q4 FY26 · 20%+ PAT growth in FY27

Management guided for 20%+ PAT growth in FY27.

Q2 FY26 · 15% revenue CAGR and 20% PAT/EPS growth for next 3-4 years

Management targets 15% revenue CAGR and 20% PAT or EPS growth over the next 3-4 years, underpinned by organic growth, brand acquisitions, and new therapy entries.

Q2 FY26 · International business contribution to reach 8-9% in a couple of years

International business, currently ~3.5% of revenue, is expected to grow to 8-9% in a couple of years, driven by hormonal product exports to Europe, UK, Australia, and other regions.

Q2 FY26 · R&D spend to remain below 2% of revenue

R&D expenditure will stay below 2% of revenue as the company scales, with ~100 scientists currently; no major increase planned.

Q3 FY26 · Revenue growth of 15% for FY26

Management reiterated annual guidance of 15% revenue growth, with 9M already at ~16%.

Q3 FY26 · PAT growth of 20% for FY26

Profit after tax growth target of 20% for the full year, with 9M PAT growth at 31%.

Q3 FY26 · New plant required by FY28-29

Management indicated need for an additional manufacturing plant in FY28-29 to support growth.